1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]piperidin-1-yl]-3-hydroxypropan-1-one
1-[4-[5-[5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl]-1-ethyl-1,2,4-triazol-3-yl]piperidin-1-yl]-3-hydroxypropan-1-one
PubChem CID: 76685059
AZD-8835 is a member of the class of triazoles that is 1H-1,2,4-triazole substituted by ethyl, 1-(3-hydroxypropanoyl)piperidin-4-yl, and 5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl groups at positions 1, 3, and 5, respectively. It is a potent inhibitor of PI3Kalpha and PI3Kdelta (IC50 = of 6.2 and 5.7 nM, respectively) which was in a phase 1 clinical trial for the treatment of advanced solid tumours (trial now discontinued). It has a role as an antineoplastic agent, a bone density conservation agent, an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and an apoptosis inducer. It is a primary alcohol, a member of triazoles, a member of pyrazines, a member of 1,3,4-oxadiazoles and a N-acylpiperidine.
Canonical SMILES
SMILES: This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Trials and conditions connected to 1620576-64-8